|
SCIENTIFIC RESEARCH
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FERTILITYBLEND: A NUTRITIONAL SUPPLEMENT FOR IMPROVING FERTILITY IN WOMEN
Lynn M. Westphal, MD, Mary Lake Polan, MD, PhD, MPH*, Aileen Sontag Trant, PhDPurpose
: To determine the impact of nutritional supplementation on female fertility. Methods: A double-blind, placebo-controlled study was initiated to determine the effects of FertilityBlend for
Women, a proprietary nutritional supplement containing chasteberry, green tea, L-arginine, vitamins (including folate) and minerals, on progesterone level, basal body temperature, menstrual cycle length, pregnancy rate
and side-effects. Results: Ninety-three (93) women, age 24-42 years, who had tried unsuccessfully to conceive for six to 36 months, completed the study. After three months, the FertilityBlend
(FB) supplement group (N=53 vs. 40 in placebo group) demonstrated a strong trend toward an increase in mean mid-luteal phase progesterone (from 8.2 to 10.4 ng/ml, p=0.06). Among women initially low in progesterone
(<12 ng/ml, N=34 in FB and 23 in placebo group), the increase in the FB group with low progesterone was highly significant (4.9 to 9.3 ng/ml; p=0.005). The average number of days in cycle with basal temperatures over
98F during luteal phase also increased significantly in the overall FB group (5.5 to 8.1 days, p=0.006). Among women starting with short cycles (<27 days, N=15 in FB and N=9 in placebo group), mean cycle length
increased significantly in the FB group (from 24.2 to 27.6 days; p<0.001). Among women with longer cycles (>32 days, N=11 in FB and 6 in placebo group), cycles tended to shorten in the FB group (from 41.6 to
31.7; p=0.02). The placebo group overall (N=40) did not show any notable changes after treatment, in any of the parameters studied. After six months, 17 of the 53 women in the FB group were pregnant (32%), and four of
the 40 women in the placebo group were pregnant (10%; p<0.01). No significant side effects were noted. Conclusion: Nutritional supplementation could provide an alternative or complement
conventional fertility therapies.
To view the complete published study, click here.Clinical and Experimental Obstetrician and Gynecology. XXXIII, n. 4, July 2006.*Dr. Polan is a member of the Scientific Advisory Board and received stock options in the
company for her service. |
|
|
Clinical Studies:
- Costa M, et al. 1994. L-carnitine in ideopathic asthenospermia: a multicenter study. Andrologia 26:155-9.
- Zheng R-L and Zhang H. 1997. Effects of ferulic acid on fertile and asthenozoospermic infertile human sperm motility, viability, lipid peroxidation, and cyclic nucleotides. Free Rad Biol & Med
22(4):581-6.
- Kessopoulou E, et al. 1995. A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated with male infertility. Fertil & Steril
64(4):825-31.
- Geva E, et al. 1996. The effect of antioxidant treatment on human spermatazoa and fertilization rate in an in vitro fertilization program. Fertil & Steril 66(3):430-4.
- Dawson EB, et al. 1992. Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertil & Steril 58(5):1034-9.
- Scott R, et al. 1998. The effect of oral selenium supplementation on human sperm motility. Br J Urol 82:76-80.
- Moriyama H, et al. 1987. Studies on the usefulness of a long-term, high-dose treatment of methylcobalamin in patients with oligozoospermia. Hin Kiyo 33(1):151-6.
- Takihara H, et al. 1987. Zinc sulphate therapy for infertile male with or without varicocelectomy. Urol 29(6):638-41.
- Czeizel AE. 1998. Periconceptual folic acid containing multivitamin supplementation. Eur J Obstet Gynecol Reprod Biol 78(2):151-61.
|